Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEL-P15
- Development stage
- Preclinical
- Lead developer
- Cerapedics
- Modality
- Peptides
01
Overview
MEL-P15 is a peptide derived from **melittin**, which is the main toxic component in the venom of the European honeybee (Apis mellifera). MEL-P15 has been specifically studied for its **anti-hepatocellular carcinoma activity**, demonstrating cytotoxic effects against liver cancer cells. The mechanism of action is related to its peptide structure, which influences cell membrane permeability and induces cell death in cancer cells. Its activity is distinct from native melittin in terms of selectivity and toxicity profile[3].
Beyond the preview
Go deeper on MEL-P15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEL-P15.